324 related articles for article (PubMed ID: 29447772)
1. The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial.
Verma A; Ha ACT; Kirchhof P; Hindricks G; Healey JS; Hill MD; Sharma M; Wyse DG; Champagne J; Essebag V; Wells G; Gupta D; Heidbuchel H; Sanders P; Birnie DH
Am Heart J; 2018 Mar; 197():124-132. PubMed ID: 29447772
[TBL] [Abstract][Full Text] [Related]
2. Design and Rationale of the RELAXED (Recurrent Embolism Lessened by rivaroxaban, an Anti-Xa agent, of Early Dosing for acute ischemic stroke and transient ischemic attack with atrial fibrillation) Study.
Yasaka M; Minematsu K; Toyoda K; Yamagami H; Yoshimura S; Nagao T; Mori E; Hirano T; Hamasaki T; Yamaguchi T
J Stroke Cerebrovasc Dis; 2016 Jun; 25(6):1342-8. PubMed ID: 26987488
[TBL] [Abstract][Full Text] [Related]
3. Apixaban versus Warfarin for the Prevention of Periprocedural Cerebral Thromboembolism in Atrial Fibrillation Ablation: Multicenter Prospective Randomized Study.
Kuwahara T; Abe M; Yamaki M; Fujieda H; Abe Y; Hashimoto K; Ishiba M; Sakai H; Hishikari K; Takigawa M; Okubo K; Takagi K; Tanaka Y; Nakajima J; Takahashi A
J Cardiovasc Electrophysiol; 2016 May; 27(5):549-54. PubMed ID: 26766541
[TBL] [Abstract][Full Text] [Related]
4. Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
Duerschmied D; Brachmann J; Darius H; Frey N; Katus HA; Rottbauer W; Schäfer A; Thiele H; Bode C; Zeymer U
Clin Res Cardiol; 2018 Jul; 107(7):533-538. PubMed ID: 29679144
[TBL] [Abstract][Full Text] [Related]
5. An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial.
Lopes RD; Vora AN; Liaw D; Granger CB; Darius H; Goodman SG; Mehran R; Windecker S; Alexander JH
Am Heart J; 2018 Jun; 200():17-23. PubMed ID: 29898844
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of percutaneous left atrial appendage closure to prevent thromboembolic events in atrial fibrillation patients with high stroke and bleeding risk.
Seeger J; Bothner C; Dahme T; Gonska B; Scharnbeck D; Markovic S; Rottbauer W; Wöhrle J
Clin Res Cardiol; 2016 Mar; 105(3):225-9. PubMed ID: 26318322
[TBL] [Abstract][Full Text] [Related]
7. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
8. Anticoagulation use and clinical outcomes after catheter ablation in patients with persistent and longstanding persistent atrial fibrillation.
Liang JJ; Elafros MA; Mullen MT; Muser D; Hayashi T; Enriquez A; Pathak RK; Zado ES; Santangeli P; Arkles JS; Schaller RD; Supple GE; Frankel DS; Garcia FC; Deo R; Lin D; Riley MP; Nazarian S; Dixit S; Marchlinski FE; Callans DJ
J Cardiovasc Electrophysiol; 2018 Jun; 29(6):823-832. PubMed ID: 29513397
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
[TBL] [Abstract][Full Text] [Related]
10. Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis.
Akao M; Yasuda S; Kaikita K; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H
Am Heart J; 2021 Jun; 236():59-68. PubMed ID: 33657403
[TBL] [Abstract][Full Text] [Related]
11. Patterns of Anticoagulation Use and Cardioembolic Risk After Catheter Ablation for Atrial Fibrillation.
Noseworthy PA; Yao X; Deshmukh AJ; Van Houten H; Sangaralingham LR; Siontis KC; Piccini JP; Asirvatham SJ; Friedman PA; Packer DL; Gersh BJ; Shah ND
J Am Heart Assoc; 2015 Nov; 4(11):. PubMed ID: 26541393
[TBL] [Abstract][Full Text] [Related]
12. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report.
Lip GYH; Banerjee A; Boriani G; Chiang CE; Fargo R; Freedman B; Lane DA; Ruff CT; Turakhia M; Werring D; Patel S; Moores L
Chest; 2018 Nov; 154(5):1121-1201. PubMed ID: 30144419
[TBL] [Abstract][Full Text] [Related]
13. Oral antithrombotic therapy in atrial fibrillation associated with acute or chronic coronary artery disease.
Cairns JA; McMurtry MS
Can J Cardiol; 2013 Jul; 29(7 Suppl):S60-70. PubMed ID: 23790600
[TBL] [Abstract][Full Text] [Related]
14. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation.
Di Biase L; Callans D; Hæusler KG; Hindricks G; Al-Khalidi H; Mont L; Cosedis Nielsen J; Piccini JP; Schotten U; Kirchhof P
Europace; 2017 Jan; 19(1):132-138. PubMed ID: 28130378
[TBL] [Abstract][Full Text] [Related]
15. The impact of risk score (CHADS2 versus CHA2DS2-VASc) on long-term outcomes after atrial fibrillation ablation.
Jacobs V; May HT; Bair TL; Crandall BG; Cutler M; Day JD; Weiss JP; Osborn JS; Muhlestein JB; Anderson JL; Mallender C; Bunch TJ
Heart Rhythm; 2015 Apr; 12(4):681-6. PubMed ID: 25546809
[TBL] [Abstract][Full Text] [Related]
16. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
Piccini JP; Stevens SR; Chang Y; Singer DE; Lokhnygina Y; Go AS; Patel MR; Mahaffey KW; Halperin JL; Breithardt G; Hankey GJ; Hacke W; Becker RC; Nessel CC; Fox KA; Califf RM;
Circulation; 2013 Jan; 127(2):224-32. PubMed ID: 23212720
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
Bansilal S; Bloomgarden Z; Halperin JL; Hellkamp AS; Lokhnygina Y; Patel MR; Becker RC; Breithardt G; Hacke W; Hankey GJ; Nessel CC; Singer DE; Berkowitz SD; Piccini JP; Mahaffey KW; Fox KA;
Am Heart J; 2015 Oct; 170(4):675-682.e8. PubMed ID: 26386791
[TBL] [Abstract][Full Text] [Related]
18. Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN-AF): Methods and Design.
Rivard L; Khairy P; Talajic M; Tardif JC; Nattel S; Bherer L; Black S; Healey J; Lanthier S; Andrade J; Massoud F; Nault I; Guertin MC; Dorian P; Kouz S; Essebag V; Ellenbogen KA; Wyse G; Racine N; Macle L; Mondesert B; Dyrda K; Tadros R; Guerra P; Thibault B; Cadrin-Tourigny J; Dubuc M; Roux JF; Mayrand H; Greiss I; Roy D
Can J Cardiol; 2019 Aug; 35(8):1069-1077. PubMed ID: 31376908
[TBL] [Abstract][Full Text] [Related]
19. Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses.
Spencer RJ; Amerena JV
Am J Cardiovasc Drugs; 2015 Dec; 15(6):395-401. PubMed ID: 26062914
[TBL] [Abstract][Full Text] [Related]
20. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]